A team at the National Health Research Institutes (NHRI) has discovered a novel orally available small molecule, DBPR728, that can cut off the nutrient supply for cancer cell growth, which can serve as a new targeted therapy drug.
The research team consists of scientists from the NHRI’s Institute of Biotechnology and Pharmaceutical Research, including Chi Ya-hui (紀雅惠), Yeh Teng-kuang (葉燈光), Chen Chiung-tong (陳炯東) and Chang Chun-ping (張竣評).
Chi told a news conference at the Ministry of Health and Welfare in Taipei yesterday that the occurrence of cancer is often caused by genetic aberrations that lead to uncontrolled cell proliferation.
Photo: Chen Yi-kuan, Taipei Times
An “oncogene” is a gene that has the potential to transform normal cells into cancerous ones through genetic aberrations — including mutation, fusion and amplification, she said.
Genetic amplification refers to an increase in the number of copies of the same gene, and studies have suggested that approximately 28 percent of cancers exhibit Myelocytomatosis (MYC) oncogene amplification, Chi said, adding that they include lung cancer, breast cancer, liver cancer and prostate cancer, as well as several other types.
For cancer cells to grow, the MYC oncoprotein functions as a transcription factor, facilitating the production of enzymes required for glycolysis (the process of breaking down glucose to produce energy), she said.
Therefore, MYC overexpression (too many copies of the MYC oncoprotein) allows cancer cells to metabolize energy in low-oxygen conditions, leading to uncontrolled cell growth and high post-operative recurrence rates, ultimately reducing overall patient survival rates, she said.
However, while there are many therapies that target specific genetic mutations in cancer cells, there are still challenges in developing drugs that target several oncogenes and their cancer-driving proteins, such as the MYC oncogene, due to the intrinsic properties of its proteins, Chi said.
In an effort to suppress MYC overexpression, Chi said the team tried to exploit its “good friend,” the enzyme Aurora kinase A, which stabilizes the MYC protein, by designing small molecules that disrupt the interaction between the two proteins, leading to MYC protein degradation.
They used the molecule DBPR728 to create an inactive oral drug that is stable in the gastrointestinal tract and can be bioconverted to become active when it reaches tumor cells, she said.
Chi said administering the oral drug to mice which have tumor cells with MYC genetic amplification and overexpression showed that the drug to can efficiently induce MYC reduction and cell apoptosis (the process of programmed cell death) in just 10 days.
The drug has obtained a patent in Taiwan and the team is applying for patents in other nations, and hopefully after it passes preclinical toxicity studies and clinical trials, it can be produced as a targeted drug for cancer treatment, she said.
The team’s findings were published in the June issue of Molecular Cancer Therapeutics, a leading journal published by the American Association for Cancer Research.
GENDER ROW: The IOC has stripped the boxing association, which disqualified Lin Yu-ting at the 2023 World Championships, of its status as the sport’s global governing body The Sports Administration yesterday protested the International Boxing Association’s (IBA) stance on a gender row involving a Taiwanese fighter at the Paris Games, saying the nation’s Olympic committee was considering filing a lawsuit. A storm erupted over the participation of Lin Yu-ting (林郁婷) and Algeria’s Imane Khelif at the Paris Olympics when Khelif’s Italian opponent pulled out of their bout less than a minute into the fight after taking a barrage of punches. On Sunday, Lin beat Svetlana Staneva of Bulgaria via a unanimous decision in a featherweight quarter-final fight. The IBA on Monday said that Lin and Khelif had been disqualified from
TALLY: Sharpshooter Lee Meng-yuan won Taiwan’s first medal in Paris, taking home a bronze, while boxer Chen Nien-chin has secured at least a bronze medal Taiwanese badminton duo Lee Yang (李洋) and Wang Chi-lin (王齊麟) yesterday won the gold medal in the men's doubles final at the Paris Olympics, defeating China's Liang Weikeng (梁偉鏗) and Wang Chan (王昶). The victory made them the first Taiwanese shuttlers to win more than one Olympic medal with back-to-back gold. They were crowned champions in the event at the Tokyo Olympics three years ago. Earlier in the day, Taiwanese boxer Lin Yu-ting (林郁婷) secured her first Olympic medal in front of a crowd chanting her name, a day after fellow boxer Imane Khelif did the same, following days of online abuse
Cheaper hotel rates and delicious street food made Taipei the most affordable city in Asia to visit in the second half of this year, a travel trend analysis conducted by Leisure and Travel magazine and the Web site Kayak.com showed. Taipei and nine other Asian cities were selected as affordable travel destinations based on “average round-trip economy airfare” and “the average rate of a one-night stay in a standard double hotel room,” they said. The results of their analysis, published on Wednesday last week, showed that the average cost of a round-trip flight and one night at a hotel in Taipei was
BOWING OUT: Wang Chi-lin became the nation’s oldest Olympic gold medalist at 29, while Lee Yang said he has not changed his plan to retire at the end of this season Taiwanese badminton duo Lee Yang (李洋) and Wang Chi-lin (王齊麟), who won gold at the Tokyo Olympics in 2021, on Sunday expressed their gratitude to fans for their support after they defended their title in Paris. “The cheers of fans were huge [to me]; that’s pretty much what kept me going,” Wang told a news conference after the final. The reigning champions secured back-to-back golds by upsetting world No. 1 duo Liang Weikeng (梁偉鏗) and Wang Chang (王昶) of China in a 76-minute marathon, which ended 21-17, 18-21, 21-19. Lee shared a similar sentiment and said he was particularly touched when the audience